EUCTR2009-011756-22-IT进行中（未招募）不适用
Reinduction with liposomal anthracyclines and Capecitabine in patients with breast cancer, locally advanced (IIIA-IIIB-IIIC) HER2 negative, not obtaining a pathological complete response (<PCR) after primary chemotherapy. - ICARO 2
AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI0 个研究点开始时间: 2009年6月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patient with residual disease on breast and / or axillary lymph nodes (- Initial histologic diagnosis with pathological characterization of: Grading, RE / PGR, Ki67, p53
- •- Initial Stage IIIA, IIIB, IIIC
- •- State hormone receptor positive or negative
- •- State-negative HER2 achieved with immunohistochemical methods or in situ hybridization using fluorescence (FISH)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of cancer in the previous 10 years (except skin cancer non-melanoma or cervical carcinoma in situ radically excised).
- •- More serious illnesses.
- •- Chronic renal failure
- •- Congestive heart failure or angina pectoris even if controlled. Previous history of myocardial infarction, uncontrolled hypertension, or arrhythmia.
- •- History of psychiatric or neurological disorders including dementia and epilepsy.
- •- Infection in place.
- •- Treatment with other experimental drugs.
- •- Geographical inaccessibility to treatment and follow up.
- •- Pregnancy or lactation
研究者
相似试验
进行中（未招募）
1 期
Primary comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AMntreated patients with higher risk MDS and oligoblastic AML eligible and intended for allogeneic HCT within the next 6 monthsMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2018-002430-21-ATGWT-TUD GmbH20
进行中（未招募）
1 期
Primary comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AMEUCTR2018-002430-21-DEGWT-TUD GmbH150
已完成
不适用
eutrophil-guided dosing of anthracycline/cyclophosphamide chemotherapy in patients with breast cancer: a feasibility studybreast cancerNL-OMON34109Ikazia Ziekenhuis30
进行中（未招募）
1 期
RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36)MedDRA version: 22.0Level: LLTClassification code 10026311Term: Malignant neoplasm of ovary and other uterine adnexaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061535Term: Ovarian neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061344Term: Peritoneal neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancerEUCTR2017-004690-14-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE64
进行中（未招募）
1 期
A clinical study conducted to evaluate the safety, efficacy and tolerability of a drug called liposomal annamycin, in patients with acute myeloid leukemia, refractory in which the disease has not responded to treatments or relapsed, where the disease came back after previous treatment.Acute Myeloid LeukemiaMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2017-003969-10-PLMoleculin Biotech, Inc.75